Middle Cerebral Artery Occlusion (MCAO) Model Development Service

Are you currently facing long drug development cycles or challenges in creating translatable stroke models? Our middle cerebral artery occlusion (MCAO) models development services at Creative Biolabs help you accelerate drug discovery and obtain highly predictive preclinical data. We achieve this through advanced, precisely controlled MCAO models and comprehensive assessment platforms, streamlining your research from target validation to lead optimization. Discover how our expertise can significantly de-risk your preclinical pipeline.

Ischemic stroke represents a leading cause of mortality and long-term disability worldwide, underscoring the urgent need for effective therapeutic interventions. The MCAO model is the most widely adopted and clinically relevant preclinical model for focal cerebral ischemia. It accurately mimics the core pathological features of human stroke, including infarct formation, cerebral edema, and neurological deficits. CBL's MCAO models development services leverage over two decades of experience to provide robust, reproducible, and highly translational models, empowering drug discovery from early neuroprotection to late-stage neurorestoration. This foundational model is instrumental in bridging the gap between basic research and clinical application.

Workflow Advantages Available Models Offerings Related Services

How Our MCAO Models Development Services Can Assist Your Project

At CBL, our MCAO models development services deliver precise, reproducible, and translationally relevant data, allowing you to confidently evaluate therapeutic candidates for ischemic stroke. We provide comprehensive solutions ranging from initial model design to in-depth data analysis, ensuring robust validation of neuroprotective, thrombolytic, and neurorestorative strategies. Our expertise streamlines your preclinical development, offering clear insights into drug efficacy and safety.

Discover How We Can Help - Request a Consultation.

Workflow: From Concept to Data-Driven Decisions

Our meticulously designed workflow ensures efficiency, transparency, and scientific rigor at every stage of your MCAO model development project. We provide a comprehensive and detailed process, suitable for visualization as a flowchart, making it very clear to potential clients what is involved.

Required Starting Materials: To initiate a project, clients typically provide their specific research objectives, information on the compound(s) to be tested (e.g., mechanism of action, dose ranges, administration routes), and any desired study parameters or unique experimental hypotheses. This foundational information enables us to tailor the most relevant MCAO model and experimental design.

Fig.1 Workflow of our Middle Cerebral Artery Occlusion (MCAO) Models Development Services. (Creative Biolabs AI)

Final Deliverables: Upon project completion, you will receive a comprehensive final study report, raw data files for all assessments conducted, and a detailed statistical analysis report with interpretations and conclusions.
Estimated Timeframe: The typical timeframe for this service ranges from 8 to 16 weeks, depending on the complexity of the study design, the number of experimental groups, and the duration of the post-stroke observation period.

Why Choose Us?

Choosing CBL for your MCAO model development means partnering with a leader in preclinical stroke research. Our commitment to scientific excellence, unparalleled precision, and client success sets us apart. We leverage decades of experience and cutting-edge methodologies to provide data you can trust, accelerating your journey towards clinical breakthroughs.

Experience the Advantage - Get a Quote Today.

Customer Reviews

"Exceptional Reproducibility: Using CBL's MCAO models development services in our research has significantly improved the reproducibility of our stroke injury models, which was a critical challenge for our high-throughput screening efforts. Their meticulous approach to surgical technique and physiological monitoring delivered incredibly consistent infarct volumes and neurological deficits, allowing for clearer compound efficacy differentiation." 2 months ago, Dr. A***n

"Tailored Study Design: CBL's MCAO service significantly facilitated our study on chronic neuroinflammation post-stroke. Their team worked closely with us to customize a long-term MCAO model and integrated specific immunohistochemical readouts for microglial activation, which was exactly what we needed. The detailed reporting provided invaluable insights into our compound's immunomodulatory effects." 5 months ago, J. S***h

"Comprehensive Data & Support: We partnered with CBL for our neurorestoration project, evaluating a novel cellular therapy. The comprehensive suite of behavioral tests and advanced imaging (including DWI) provided a holistic view of functional recovery, while their expert data interpretation helped us understand the complex interplay of parameters. Their guidance throughout the project was unparalleled." 1 year ago, P. K***g

Middle Cerebral Artery Occlusion (MCAO) Models

Diverse MCAO Methodologies for Tailored Research Needs

Recognizing that different research questions demand distinct experimental approaches, we offer a comprehensive suite of MCAO methodologies, each with specific advantages:

Models	Description
Intraluminal Filament MCAO Model	This widely utilized method involves the insertion of a nylon filament into the internal carotid artery to occlude the origin of the middle cerebral artery. It allows for both transient (reperfusion) and permanent ischemia, closely mimicking clinical scenarios of reperfusion injury or persistent occlusion. Advantages: High reproducibility, well-established protocols, adaptability to various animal species (rodents, non-human primates), and the ability to study both acute and chronic phases of stroke. Applications: Ideal for evaluating neuroprotective strategies, thrombolytic agents, and agents targeting reperfusion injury.
Photothrombotic MCAO Model	The photothrombotic model offers a highly focal and reproducible cortical ischemic lesion by photoactivating a dye (e.g., Rose Bengal) in the cerebral vasculature, inducing localized thrombosis. Advantages: Minimally invasive, high spatial precision, reduced mortality rates compared to filament models, and precise control over infarct size and location. Applications: Excellent for studying focal cortical ischemia, microvascular dysfunction, and targeted neuronal plasticity or repair mechanisms.
Endovascular Clot Embolism Model	This advanced model involves injecting an artificial clot directly into the cerebrovasculature, providing a more translationally relevant representation of embolic stroke. Advantages: Closely mimics the etiology of human embolic stroke, enabling studies on clot lysis, mechanical thrombectomy, and downstream effects of embolization. Applications: Optimal for evaluating novel thrombolytic agents, endovascular devices, and strategies to prevent re-embolization.

Critical Endpoints and Comprehensive Assessment

Translational success hinges on rigorous and multifactorial endpoint analysis. Our MCAO model development services include comprehensive assessments to provide a holistic view of therapeutic efficacy:

Assessment	Description
Neurological Deficit Scoring	Standardized behavioral tests (e.g., Modified Neurological Severity Score (mNSS), Garcia score, limb placement tests, adhesive removal tests) to quantify functional impairments and recovery over time.
Infarct Volume Quantification	Precise measurement of ischemic lesion size using histopathological techniques (e.g., TTC staining) or advanced imaging modalities (e.g., MRI diffusion-weighted imaging (DWI), T2-weighted imaging).
Histopathological Analysis	In-depth evaluation of neuronal survival (Nissl staining), neuroinflammation (IHC for microglia/astrocyte activation markers), blood-brain barrier integrity, and vascular remodeling (angiogenesis).
Behavioral and Cognitive Testing	Advanced assessments for long-term functional recovery, including motor coordination (rotarod), grip strength, anxiety (open field), and cognitive function (novel object recognition, Morris Water Maze).
Molecular and Biochemical Biomarkers	Analysis of inflammatory cytokines, oxidative stress markers, protein expression, and gene transcription to elucidate underlying mechanisms of action.

What We Can Offer

At CBL, we provide a comprehensive suite of solutions tailored to your MCAO model development needs. We offer various MCAO induction methodologies, a wide range of analytical endpoints, and expert consultation to ensure your project's success. Our offerings are designed to deliver actionable data and accelerate your preclinical stroke research.

End-to-End MCAO Solutions: Experience a seamless, one-stop service from initial project consultation and customized model design, through precise in vivo MCAO studies, to robust data analysis and comprehensive reporting.
Optimized Workflow Efficiency: Benefit from highly efficient upstream model induction and streamlined downstream assessment processes, engineered to ensure rapid and reliable data generation for your critical timelines.
Scalable Study Capacity: Leverage our capability to handle projects of varying scales, from targeted exploratory studies to larger, comprehensive efficacy trials, ensuring your research progresses seamlessly without bottlenecks.
Unwavering Quality & Reproducibility: Rely on our well-established quality systems, adherence to Quality-by-Design (QbD) principles, and utilization of advanced process analytical techniques (PAT) to guarantee consistent, highly reproducible MCAO models and data.
Rigorous Model Stability Verification: Trust in our comprehensive assessment and documentation of model stability, including precise pre-ischemic physiological parameter monitoring and detailed post-ischemic neurological deficit evaluations, ensuring reliability throughout your study.
Flexible Study Modalities: Access our expertise in running MCAO models in various modes—transient, permanent, and highly focal photothrombotic—allowing us to optimize ischemic conditions and maximize translational relevance for your specific research goals.
Tailored Customization: Benefit from our unparalleled ability to customize every aspect of your MCAO model, from choice of species and strain to specific lesion locations and comprehensive endpoint assays, perfectly matching your unique research objectives.

Related Services

Beyond our core MCAO models development services, CBL offers a suite of complementary preclinical research services essential for comprehensive stroke drug discovery and development. These services can be seamlessly integrated with your MCAO studies to provide a holistic understanding of your compound's efficacy, safety, and mechanism of action.

Ready to discuss your preclinical stroke research needs? Our expert team is here to help you design and execute studies that deliver clear, actionable results.

Contact Our Team for More Information and to Discuss Your Project.

For Research Use Only. Not For Clinical Use.

In Vivo Services

Hot Products

Antibodies

Cells

Kits

Tracers

Gene Therapy Tools

Biospecimens

Cell Assay Reagents